Seratrodast

Seratrodast
Clinical data
Trade namesBronica in Japan, Changnuo, Mai Xu Jia, Quan Kang Nuo in China and as Seradair in India. .[1]
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth (tablets, granules)
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding>96%
Elimination half-life22 hours
Identifiers
  • 7-Phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.220.176 Edit this at Wikidata
Chemical and physical data
FormulaC22H26O4
Molar mass354.446 g·mol−1
3D model (JSmol)
  • CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C
  • InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24) ☒N
  • Key:ZBVKEHDGYSLCCC-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Seratrodast (development name, AA-2414; marketed originally as Bronica)[2] is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma.[3][4] It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997.[5] As of 2017 seratrodast was marketed as Bronica in Japan, and as Changnuo, Mai Xu Jia, Quan Kang Nuo in China.[1]

Unlike thromboxane synthase inhibitors such as ozagrel, seratrodast does not affect thrombus formation, time to occlusion and bleeding time.[6] Seratrodast has no effect on prothrombin time and activated partial thromboplastin time, thus ruling out any action on blood coagulation cascade.[7]

  1. ^ a b "Seratrodast international brands". Drugs.com. Retrieved 8 March 2017.
  2. ^ "Seratrodast". AdisInsight. Retrieved 8 March 2017.
  3. ^ Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nihon Rinsho. Japanese Journal of Clinical Medicine (in Japanese). 54 (11): 3045–8. PMID 8950952.
  4. ^ Hada S, Hashizume M, Nishii S, Yoshioka F, Yasunaga K (January 1993). "[Study on the inhibitory effect of AA-2414 on platelet aggregation and its clinical effect in asthmatic patients]". Arerugi [Allergy] (in Japanese). 42 (1): 18–25. PMID 8457165.
  5. ^ Dogné JM, de Leval X, Benoit P, Delarge J, Masereel B (2002). "Thromboxane A2 inhibition: therapeutic potential in bronchial asthma". American Journal of Respiratory Medicine. 1 (1): 11–7. doi:10.1007/bf03257158. PMID 14720071. S2CID 40324562.
  6. ^ Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, et al. (May 2004). "Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time". The Journal of Pharmacology and Experimental Therapeutics. 309 (2): 498–505. doi:10.1124/jpet.103.063610. PMID 14742735. S2CID 46723447.
  7. ^ Samara EE (1996). "Seratrodast (AA-2414)—A Novel Thromboxane-A2 Receptor Antagonist". Cardiovascular Drug Reviews. 14 (3): 272–85. doi:10.1111/j.1527-3466.1996.tb00231.x.